RSSL responds to change in Good Distribution Practice guidelines

Published: 3-Apr-2013
Training & Education Regulatory Logistics

Extra dates for courses covering the changes for distributors wishing to ensure their licence meets the new requirements


The new 'Commission Guidelines on Good Distribution Practice (GDP) of Medicinal Products for Human Use' introduce massive changes in the expectations on companies involved in distributing pharmaceutical products. The new guidelines have radically altered the working landscape for wholesale distributors, freight forwarders, agents and brokers, and everyone else involved in the distribution of pharmaceutical products.

Distributors that wish to ensure that their licence meets the new requirements, will have a lot to do to make sure they meet the standards that the industry is trying to set.

RSSL ran its first course covering the changes in the GDP guidelines just a day after they were published last month. Extra dates for courses covering these important changes have been set for 9 April, 21 May and 13 June.

  • Companies:
  • Reading Scientific Services Ltd
See more

You may also like

Training & Education

RSSL announces new Innovation Hub to support biotech companies

Read more
The hub has a dedicated laboratory space and flexible support services for smaller biotech organisations to accelerate product development

Trending Articles

  1. IMed Consultancy helps Toby Orthopaedics navigate UK regulations Regulatory consultancy ensures compliance and confidence for Miami-based company
  2. IMed supports K2 medical systems in their EU MDR transition Consultancy firm helps K2 navigate the complex regulatory process to achieve Article 97 compliance
  3. Cleancube multi: Guardtech’s container facilities support NHS aseptic pharmacies Award-winning mobile cleanrooms offer fast, flexible solutions for facility upgrades
  4. Ardena's Oss nanomedicine facility gains full GMP approval from the Dutch Healthcare Authority The pharmaceutical manufacturing facility can produce advanced nanoparticle drug delivery systems, including lipid-based, polymeric and metal oxide nanoparticles
  5. Pfizer gains European Commission approval for haemophilia A and B drug, Hympavzi The subcutaneous therapeutic is the first and only anti-tissue factor pathway inhibitor approved for the treatment of haemophilia A or B, and is available in an auto-injector format

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

You may also like

Training & Education

RSSL announces new Innovation Hub to support biotech companies

The hub has a dedicated laboratory space and flexible support services for smaller biotech organisations to accelerate product development
Training & Education

RSSL announces new state-of-the-art facility

Opening as part of ambitious expansion plan ew facility will increase capacity to aid RSSL in meeting the growing demand of its global client base
Regulatory

RSSL wins Employer of the Year Award

RSSL was crowned Employer of the Year in recognition of its outstanding dedication to staff development, engagement and wellbeing
Regulatory

RSSL Wins Business of the Year Award

The judges praised its forward-thinking approach and strong commercial performance
Training & Education

RSSL QP training - achieve your QP ambitions

Starting your QP journey with RSSL
Regulatory

Ethypharm and RSSL partnership fast-tracks priority medicine

Ethypharm has collaborated with RSSL to accelerate the manufacture and batch release of fentanyl injection
Regulatory

Adequately establishing contamination risk in drug products

Recent changes within the United States Pharmacopoeia (USP) and European Pharmacopoeia (EP) put emphasis on risk assessment for the likelihood of contamination as opposed to enforcing mandatory testing in drug products, Alan Cross, technical specialist, metals laboratory at RSSL, explains
Subscribe now